|
KMID : 0376419950190010079
|
|
Chonbuk University Medical Journal
1995 Volume.19 No. 1 p.79 ~ p.96
|
|
|
Effect of Rebamipide(Mucosta) on Chronic Gastritis and Peptic Ulcer
|
|
|
|
|
Abstract
|
|
|
Ulcer development or resistance to ulceration depends on the balance between aggressive factors(principally secreted gastric acid and pepsin) and factors that comprise mucosal defense or mucosal resistance to ulceration (gastric mucus,
bicarbonate
ions,
gastric mucosal barrier, mucosal blood flow, and prostaglandins). H₂blockers have been the first drug of choice in the non-surgical cares of peptic ulcer patients, but have raised the clinical problem of recurrence promptly following
discontinuation of
use. Rebamipide[OPC-12579, 2-(4-chlorobenzoyla-mino)-3-[2(1H)-quinolinon-4-yl]-propionic acid] was studied for its efficacy to prevent the gastric mucosal damage induced by several necrotizing agents. OPC-12579(Mucosta) strongly attenuates
gastric
injury in vivo by inhibition of superoxide production in polymorphonuclear neutrophils, or by scavenging hydroxyl radicals, or by both.
We evaluated the effect of Rebamipide(Mucosta) on the chronic gastrits and peptic ulcer disease. Rebamipide was orally administered 100㎖three tines a day for 8 weeks to 20 patients with benign chronic gastritis and peptic ulcer. General
improvement
rate of Rebamipide was remarkable in 50% of patients and effectiveness rate of Rebamipide was 80% after 8 weeks of treatment. No significant clinical side effects had been noticed
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|